Background and objective: Systemic sclerosis (SSc) is a complex autoimmune disease commonly associated with pulmonary hypertension (PH). When associated with elevated pulmonary artery wedge pressure (PAWP), pulmonary artery pressure (PAP) is either inproportion (post-capillary PH) or higher than expected (combined PH) relative to the increased PAWP. Methods: Patients from the PHAROS registry (a prospective observational cohort of SSc-PH patients) who had mean PAP ≥ 25 and PAWP > 15 on right heart catheterization were stratified based on diastolic pressure gradient (DPG). Kaplan-Meier analysis was performed to compare survival and PH-related hospitalization. Baseline factors were compared between patients dying and those who survived using Cox regression analysis. Results: A total of 59 patients were included, of whom 21 (36%) patients were classified as combined PH and 38 (64%) had post-capillary PH. No baseline characteristics were significantly different between the two groups. There were no differences in survival or PHrelated hospitalization between the groups. The only baseline factor independently associated with death was lower 6-min walk distance (6MWD) (hazard ratio (HR): 1.33 per 25 m decrease, 95% CI: 1.11-1.59, P = 0.002). PH-specific medications were started during follow-up in significantly more patients in the combined PH group compared with the post-capillary group (86% vs 50%, P = 0.01). Conclusion: Outcomes were similar between SSc patients with post-capillary PH and combined pre-and post-capillary PH. 6MWD at baseline can predict risk for death in SSc patients with PH and an elevated
INTRODUCTION
Systemic sclerosis (SSc, scleroderma) is a heterogeneous multiorgan disease that is commonly associated with pulmonary hypertension (PH). SSc-PH may be pulmonary arterial hypertension (PAH, WHO Group 1) or PH caused by left heart disease (LHD) (WHO Group 2) or interstitial lung disease (ILD)/hypoxia (WHO Group 3). SSc patients with Group 2 PH can have either elevated pulmonary artery pressures (PAPs) due to systolic left ventricular (LV) dysfunction or from diastolic LV dysfunction (also known as heart failure with preserved ejection fraction, HFpEF). 1 Diastolic dysfunction is a common complication of SSc, with an estimated prevalence of 55%, which is higher than in individuals without SSc. 2 LHD is the most common cause of PH in the general population 3 and at least 10% of SSc-PH patients have PH from LHD, 4 but this may be underestimated. 5 Patients with Group 2 SSc-PH are defined by a mean PAP (mPAP) of ≥25 mm Hg with an elevated pulmonary artery wedge pressure (PAWP, also known as pulmonary capillary wedge pressure (PCWP)) of >15 mm Hg, and can be further characterized as having post-capillary PH or combined post-and pre-capillary PH (formerly known as 'out-of-proportion PH', heretofore referred to as 'combined PH'). 3 Characteristics and survival of SSc patients with an elevated PAWP has not been well described, and reasons why some patients have post-capillary PH and others have combined PH are undefined. We undertook this analysis to characterize SSc-PH patients with an elevated PAWP and to explore differences between postcapillary PH and combined PH, with a specific hypothesis that those with combined PH have a poorer survival. 6 
METHODS

Patient selection
This study utilized the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) registry, an ongoing prospective, longitudinal multicentre observational study of SSc patients at risk for or with incident PH. 4 Twenty-nine participating SSc centers in the United States obtained institutional review board approval and all patients provided written informed consent prior to enrolment in the registry. Inclusion criteria for analysis were mPAP ≥ 25 mm Hg and PAWP > 15 mm Hg on their diagnostic right heart catheterization (RHC) performed within 6 months of enrolment.
The baseline time point was defined as the date of the patient's inclusion of RHC. This analysis contained subjects enrolled in the registry by 14 May 2014. A haemodynamic definition was selected for this analysis rather than WHO classification; therefore, patients with ILD were included if their PAWP was >15 mm Hg.
RHC measurements and definitions
Data collected by RHC included measurement of systolic, diastolic and mPAPs, PAWP and cardiac output (CO). Pulmonary vascular resistance (PVR) was calculated as: PVR = (mPAP − PAWP)/CO Transpulmonary gradient (TPG) was calculated as: TPG = mPAP − PAWP Diastolic pressure gradient (DPG) was calculated as: DPG = diastolic PAP − PAWP Using a classification scheme suggested for LHDassociated PH in the general population, the group as a whole was divided into subgroups based on DPG, with an elevated gradient suggesting that the PAP was increased out-of-proportion to the PAWP, whereas a normal DPG implies that the PAP elevation was accounted for by the high PAWP. 7 Patients with postcapillary PH were defined as having a DPG of <7 mm Hg, whereas those with combined PH were defined as having a DPG of ≥7 mm Hg. 3 A sensitivity analysis was conducted using TPG to define groups (TPG ≤ 12 mm Hg = post-capillary PH, TPG > 12 mm Hg = combined PH).
Statistical analysis
Baseline characteristics (demographics, medication use, pulmonary function tests, haemodynamics and SSc disease characteristics) were compared between the post-capillary PH and the combined PH groups using unpaired t-tests or chi-square test. In a post hoc analysis, baseline characteristics of those started on PH-specific medications (endothelin receptor antagonist, prostacyclin analogue and phosphodiesterase-5 (PDE-5) inhibitor) during follow-up were compared with those not receiving these medications.
In patients with ≥6 months of follow-up, we investigated the elevated PAWP group as a whole, comparing baseline factors between patients dying and those who survived during follow-up using Cox regression analysis. Examining the proportionality assumptions of the Cox proportional hazards model using both log-log curves and Schoenfeld residuals demonstrated that all assumptions were met. Multivariate analysis was performed with all univariate factors with a P < 0.05 included; stepwise regression with backward elimination was conducted, with a P threshold for elimination = 0.20. Collinearity between haemodynamic variables was assessed using variance inflation factors (VIFs), with a VIF of >10 indicating that variables were collinear. 8 There was no significant collinearity between mPAP, CO and PVR. Survival and time to first PHrelated hospitalization between the post-capillary and the combined PH groups were compared with KaplanMeier analysis. A hospitalization was considered PHrelated if it was for heart failure, volume overload, initiation of PH-specific medication or a complication of PH-specific medication.
All analyses were performed using Graph Pad Prism (version 5, GraphPad Software, La Jolla, CA, USA) and Stata (version 13, College Station, TX, USA), and a P value <0.05 was considered to be statistically significant. Institutional review board approval was obtained for this analysis (Tulane IRB #685867). Some of these results have been previously published as an abstract. 9 
RESULTS
Baseline characteristics
Of the 298 patients in PHAROS with PH on RHC, 59 met inclusion criteria, with 21 (36%) being classified as combined PH based on their DPG and 38 (64%) classified as post-capillary PH. Only two patients (3%) had an left ventricular ejection fraction (LVEF) < 45%. Patients with a DPG ≥ 7 mm Hg had higher mPAP, TPG and PVR (Table 1 ) compared with those with a DPG < 7 mm Hg. There were no significant differences in any of the measured baseline characteristics between the two groups (all P > 0.05). Although not significantly different, those with combined PH had a higher forced vital capacity (FVC) (P = 0.09) and were more likely to have a limited disease subtype (P = 0.17). During follow-up, 50% of patients in the post-capillary PH group were started on PH-specific medications, compared with 86% of patients in the combined PH group (n = 0.01). The median time on medication during the observation period was 1.8 years (interquartile range (IQR): 1.1, 3.8). Patients were treated with endothelin receptor antagonists (n = 20), PDE-5 inhibitors (n = 28), inhaled prostanoids (n = 5) and parenteral prostanoids (n = 7). Eleven were treated with two medications and five were on triple therapy. When TPG was used to define combined PH (TPG > 12 mm Hg) versus post-capillary PH (TPG ≤ 12 mm Hg), the results were similar to those obtained using DPG to dichotomize groups (Table S1 , Supplementary Information).
Patients started on PH-specific medications (n = 37) had a significantly higher mPAP (40.0 AE 13.8 mm Hg vs 31.3 AE 5.2 mm Hg, P = 0.006; Table 2 ), DPG (9.5 AE 9.9 vs 3.8 AE 3.5, P = 0.01), TPG (20.1 AE 13.5 vs 11.6 AE 4.6, P = 0.006) and PVR (5.0 AE 3.9 Wood units vs 2.3 AE 1.4 Wood units, P = 0.003) compared with those not started on these medications (n = 22). There was no difference in terms of CO or PAWP between these groups. No measured baseline characteristics (demographics, SSc disease characteristics or pulmonary function test variables) were associated with likelihood to start PH-specific medications. Interestingly, New York Heart Association (NYHA) functional class at baseline did not correlate with whether a PH-specific medication was started (P = 0.82).
Survival analysis
For the survival analysis, there were a total of 163.3 patient-years at risk; the median time at risk was 2.3 years. Over a 5-year observation period, 18 patients (31%) died, with survival rates of 84.7% at 1 year, 64.7% at 3 years, and 61.2% at 5 years (Fig. 1) . For the PAWP > 15 group as a whole, univariate factors associated with death included male sex (hazard ratio (HR): 2.94, 95% CI: 1.11-7.69, P = 0.03; Table 3 ), NYHA functional class (HR: 2.50, 95% CI: 1.30-4.79, P = 0.006), lower 6-min walk distance (6MWD) (HR: 1.33 per 25 m decrease, 95% CI: 1.15-1.54, P < 0.0001) and higher PAWP (HR: 1.16 per 1 mm Hg change, 95% CI: 1.06-1.28, P = 0.002). In a multivariate analysis, the only baseline parameter independently associated with CO , diffuse capacity for carbon monoxide; DPG, diastolic pressure gradient; EF, ejection fraction; FVC, forced vital capacity; MMF, mycophenolate; mPAP, mean pulmonary artery pressure; NYHA, New York Heart Association; PAWP, pulmonary artery wedge pressure; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; RHC, right heart catheterization; SSc, systemic sclerosis; TPG, transpulmonary gradient.
death was 6MWD (HR 1.33 per 25 m decrease, 95% CI: 1.11-1.59, P = 0.002; Table 3 , Fig. 2 ).
Twelve (32%) patients in the post-capillary PH group and six (29%) of those in the combined PH group died over a 5-year observation period. There was no significant difference in survival between the two groups (P = 0.66; Fig. 3A ). There was also no difference in death or PH-related hospitalization between the postcapillary PH and the combined PH groups (P = 0.27; Fig. 3B ).
DISCUSSION
In this analysis, which is the first study investigating post-capillary PH and combined PH in SSc patients, we found that baseline characteristics were similar between these two groups, although the combined PH group was more likely to be started on a PH-specific medication. We also found that there was no difference in outcomes between those with post-capillary PH and combined PH. Lastly, this study demonstrates that lower baseline 6MWD is an independent predictor of death in SSc-PH patients with an elevated PAWP.
As only two patients had an LV ejection fraction < 45%, the majority of patients in this study can be considered to have diastolic dysfunction, which is consistent with prior literature. [10] [11] [12] In echocardiographic studies of unselected patients, diastolic dysfunction is present in 23-62% of SSc subjects, with most estimates around 50%, which is a higher prevalence than healthy controls. 2, 10, [13] [14] [15] [16] [17] In SSc patients, diastolic dysfunction tends to worsen over time, 13, 15 parameters of diastolic function correlate with exercise performance 14, 18 and LV diastolic dysfunction is independently associated with risk for death. 15, 17 Most of these studies, however, did not have a large number of PH patients, so the contribution of LHD to PH in SSc patients is less well defined. Prior interim analysis of the PHAROS cohort demonstrated that 10% of the PH patients were classified as having WHO Group 2 disease, 4 but with a larger data set we have shown that 20% of SSc-PH patients in this cohort have an elevated PAWP.
It is not clear why some patients with an elevated PAWP have post-capillary PH and others develop combined pre-and post-capillary PH. It is assumed that in susceptible patients, long-standing left atrial hypertension leads to remodelling in the pulmonary arteries, resulting in a PAP that is out-of-proportion to the PAWP. In SSc, the case may be more complex as patients with LHD may also have a component of PAH (WHO Group 1) or ILD (WHO Group 3). On the other hand, SSc patients with PAH might have mild diastolic dysfunction with an elevated PAWP. In comparison to other patients with HFpEF-PH, patients with SSc-PH and a high PAWP appear to be younger 19, 20 and are less likely to be in functional class III/IV. 20 Haemodynamically, mPAP and CO seem to be similar, but our cohort appears to have lower PAWP and higher PVR compared with a large cohort of HFpEF-PH patients without SSc. 20 Interestingly, there were no differences in any of the measured baseline characteristics between the postcapillary PH and the combined PH groups. We expected outcomes to be worse in those with combined PH, 6 but found that survival and time to PH-related hospitalization were similar in both groups. We recently found that survival was similar between SSc patients with Group 1 PH ('pre-capillary') and Group 2 PH. 21 In the high PAWP group as a whole, the only baseline parameter that was independently associated with risk for death was a low 6MWD. For each 25-m decrease in baseline 6MWD, there was a 33% increase in risk for death over the 5-year observation period. Although well accepted as an important measure of functional status and outcome in other forms of PAH, 22 the use of the 6-min walk test (6MWT) is controversial in SSc. This is because there are many SSc manifestations that can lead to an impairment in 6MWD, including heart, lung, joint and muscle disease. 23 6MWD has been shown to correlate with disease activity and quality of life scores, but poorly with lung function parameters. 24 Additionally, the 6MWD appears insensitive to change in haemodynamics when SSc patients are treated with PH-specific medications. 25 However, there is excellent reproducibility of the 6MWT in SSc patients 26 and as a global marker of functional status it may be helpful in determining prognosis. We demonstrate for the first time that in SSc-PH patients with an elevated PAWP, 6MWD at the time of PH diagnosis may be useful to identify patients at higher risk for death.
Treatment with PH-specific medications (endothelin receptor antagonists, prostacyclin analogues, PDE-5 inhibitors and soluble guanylate cyclase stimulators) is generally advised against in patients with LHD and an elevated PAWP. 3 This recommendation is based on the fact that most clinical studies of PH-specific medications in LHD have failed to show benefit. [27] [28] [29] In our observational study, the majority of SSc patients Variables given in bold were included in the multivariate model. Sex was removed from the stepwise backward regression as P < 0.20.
-, variable not included in multivariate analysis; 6MWD, 6-min walk distance; CI, confidence interval; DL CO , diffuse capacity for carbon monoxide; DPG, diastolic pressure gradient; FVC, forced vital capacity; HR, hazard ratio; mPAP, mean pulmonary artery pressure; NYHA, New York Heart Association; PAWP, pulmonary artery wedge pressure; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; SSc, systemic sclerosis. Figure 2 Kaplan-Meier survival curves for the group stratified by median 6-min walk distance (6MWD). Those with a lower 6MWD at baseline had significantly worse survival. , 6MWD > 334; , 6MWD < 334; P = 0.002.
with PH and an elevated PAWP were treated with PH-specific medications, with more being treated in the combined PH group. As PH pathogenesis in SSc may be a combination of diastolic dysfunction, pulmonary arterial vasculopathy and PH associated with parenchymal lung disease, treatment paradigms for patients with standard HFpEF-PH may not apply to patients with SSc. However, randomized trials are needed in SSc patients with an elevated PAWP to determine the clinical utility of treatment with PHspecific medications.
Our study has limitations that must be acknowledged. Although 59 patients is a reasonable number of patients for a rare condition (i.e. SSc with PH and an elevated PAWP), this is a small sample size and the risk for Type 2 error exists. With a larger sample size, a baseline factor such as FVC may have been significantly different between the groups. While the patients included here were cared for in specialized SSc centres, we do not feel that this is a limitation as SSc patients with PH are commonly seen in referral centres. The PHAROS registry database did not collect some variables that may be important when comparing patients with an elevated PAWP, such as co-morbidities (e.g. sleep apnoea and coronary artery disease), nor did it collect in-depth echocardiographic diastolic dysfunction parameters. Right atrial pressure, a haemodynamic parameter known to predict outcomes, 30 was also not collected in this study. RHC tracings were not centrally reviewed and there may have been mismeasurements of PAWP, particularly in patients with ILD and/or obesity. However, RHCs were done in referral centres and any potential mismeasurements are likely reflective of 'real-world' practice. Additionally, although PH-related hospitalizations were defined a priori, cause of hospitalization was not centrally adjudicated. Following current recommendations, 3 we used a DPG of 7 as a cut-off value between post-capillary PH and combined PH, rather than TPG. However, as mirrored in this analysis, neither has been consistently shown to predict mortality. 31 In conclusion, survival and PH-related hospitalizations were similar between SSc patients with postcapillary PH and combined pre-and post-capillary PH. Therefore, using the DPG in SSc-PH patients with an elevated PAWP was not able to accurately phenotype or prognosticate likely due to the mixed aetiologies of elevated PAP in SSc. As many patients with SSc-PH have concomitant ILD, proper PAWP measurement is critical when interpreting their haemodynamics. 6MWD at the time of diagnosis can be used to predict risk for death in SSc patients with PH and an elevated PAWP. Patients with combined PH were more likely to be started on PH-specific medications, although 50% of patients with post-capillary PH were also treated at some point during follow-up. The clinical benefit of treating this subgroup specifically in SSc patients needs further exploration, as the multifactorial aetiology of their PH may be different than those with HFpEF-PH.
